During perimenopause, the risk of developing depressive episodes, even of a severe nature, increases. The possibility of one or more depressive episodes occurring during perimenopause is greater than during the premenopausal period, particularly in patients with mood disorders. Women with a postmenopausal major depressive episode showed a better response to antidepressant therapy when given in combination with hormone replacement therapy. This can be explained by the neurophysiopathological correlates of menopausal depression, which may also improve with the administration of liposomes. Phospholipid liposomes added to standard antidepressant drug treatment have proven to be effective on anxi¬ety, depression, somatic symptoms and menopausal syndrome. We describe the case of a 51-year-old woman diagnosed with major depressive disorder (MDD), suffering from a postmenopausal depressive episode, who showed symptom remission after one month of therapy with phospholipid liposomes at a daily dose of 56 mg (2 vials per day), added to standard antidepressant therapy. She showed improvement to remission of depressive symptoms, mainly including in-somnia, depressed mood, anxiety and agitation, and a reduction of vasomotor symptoms. In addition to an improvement in depressive symptoms, phospholipid liposomes added to standard antidepressant treatment may reduce psychic and vasomotor symptoms that occur in menopause in patients with MDD. Further studies are needed to evaluate the efficacy of phospholipid liposomes in the treatment of menopausal depression.

Add-on phospholipid liposomes in a postmenopausal depressive episode of a patient with major depressive disorder / Girardi, P.; Fiasche, F.; Zocchi, C.; Del Casale, A.. - In: MINERVA PSYCHIATRY. - ISSN 2724-6612. - 62:4(2021), pp. 1-5. [10.23736/S2724-6612.21.02219-3]

Add-on phospholipid liposomes in a postmenopausal depressive episode of a patient with major depressive disorder

Girardi P.;Zocchi C.;Del Casale A.
2021

Abstract

During perimenopause, the risk of developing depressive episodes, even of a severe nature, increases. The possibility of one or more depressive episodes occurring during perimenopause is greater than during the premenopausal period, particularly in patients with mood disorders. Women with a postmenopausal major depressive episode showed a better response to antidepressant therapy when given in combination with hormone replacement therapy. This can be explained by the neurophysiopathological correlates of menopausal depression, which may also improve with the administration of liposomes. Phospholipid liposomes added to standard antidepressant drug treatment have proven to be effective on anxi¬ety, depression, somatic symptoms and menopausal syndrome. We describe the case of a 51-year-old woman diagnosed with major depressive disorder (MDD), suffering from a postmenopausal depressive episode, who showed symptom remission after one month of therapy with phospholipid liposomes at a daily dose of 56 mg (2 vials per day), added to standard antidepressant therapy. She showed improvement to remission of depressive symptoms, mainly including in-somnia, depressed mood, anxiety and agitation, and a reduction of vasomotor symptoms. In addition to an improvement in depressive symptoms, phospholipid liposomes added to standard antidepressant treatment may reduce psychic and vasomotor symptoms that occur in menopause in patients with MDD. Further studies are needed to evaluate the efficacy of phospholipid liposomes in the treatment of menopausal depression.
2021
depressive disorder; major; antidepressive agents; menopause; anxiety
01 Pubblicazione su rivista::01a Articolo in rivista
Add-on phospholipid liposomes in a postmenopausal depressive episode of a patient with major depressive disorder / Girardi, P.; Fiasche, F.; Zocchi, C.; Del Casale, A.. - In: MINERVA PSYCHIATRY. - ISSN 2724-6612. - 62:4(2021), pp. 1-5. [10.23736/S2724-6612.21.02219-3]
File allegati a questo prodotto
File Dimensione Formato  
Girardi_Add-on-phospholipid-liposomes_2021 .pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 449.82 kB
Formato Adobe PDF
449.82 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1652390
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact